TrialsgrambetaRCTs are beautiful

Fluids & resuscitation

Balanced crystalloids, hydroxyethyl starch harm and albumin trials.

  • 2022PLUS⁠Balanced crystalloidsIn 5,037 ICU patients, Plasma-Lyte 148 did not change 90-day mortality versus saline.21.8% vs 22.0%Read →
  • 2021BaSICS⁠Balanced crystalloidsIn 11,052 ICU patients, Plasma-Lyte did not reduce 90-day mortality compared with saline, with possible harm in traumatic brain injury.HR 0.9795% CI 0.90-1.05Read →
  • 2018SMART 2018⁠Balanced crystalloidsIn 15,802 ICU patients, balanced crystalloids reduced the composite of major adverse kidney events at 30 days versus saline.OR 0.91Read →
  • 2012CHEST Core⁠Hydroxyethyl starchIn 7,000 ICU patients, 6% HES 130/0.4 did not reduce 90-day mortality versus saline, but increased renal-replacement therapy.18% vs 17%Read →
  • 20126S⁠Hydroxyethyl starchIn 804 patients with severe sepsis, 6% HES 130/0.42 increased 90-day death or dialysis versus Ringer's acetate.RR 1.1795% CI 1.01-1.36Read →
  • 2004SAFE 2004 Core⁠Albumin vs crystalloidIn 6,997 ICU patients requiring fluid resuscitation, 4% albumin did not change 28-day mortality versus 0.9% saline, with harm in the traumatic brain injury subgroup.RR 0.9995% CI 0.91-1.09Read →